Pharmacovigilance and signal detection FAERS semaglutide disproportionality (broad): A FAERS-based disproportionality analysis of semaglutide reports through mid-2023 identified multiple unexpected adverse event signals and explicitly notes that some signals were not mentioned in the drug insert, including polycystic ovaries. The analysis highlights typical spontaneous-reporting limitations (missing age, outcome data)
Switching From Semaglutide to Tirzepatide If youre currently taking semaglutide and wondering whether switching to tirzepatide makes sense, youre not alone
Shamsah Amersi, an OB-GYN who specializes in womens health and metabolic medicine, describes it this way: The body responds to consistency, not intensity. In her practice, she starts patients at 0.05 to 0.1 mg of semaglutide weekly and watches for three things: Appetite changes : Most patients notice subtle but real shifts within two to four weeks
Comparison of Mounjaro vs
Imaging studies and body composition scans (DEXA scans and bioelectrical impedance analysis) can quantify exactly how much fat you've lost versus how much muscle you've maintained or gained
